ReviewThe Journal of clinical investigation2024
Considerations for the application of polygenic scores to clinical care of individuals with substance use disorders.
Review in The Journal of clinical investigation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Moderation of treatment outcomes by polygenic risk for alcohol-related traits in placebo-controlled trials of topiramate.Alcohol, clinical & experimental research · 2025Trial
- Predicting accumulation and age at onset of amyloid-β from genetic risk and resilience for Alzheimer's disease.EBioMedicine · 2026Article
- Behavioral and transcriptomic markers of susceptibility to escalate fentanyl intake.Translational psychiatry · 2026Article
- Indirect Genetic Effects on Alcohol Use Disorder and Nicotine Dependence.medRxiv : the preprint server for health sciences · 2026Article
- Morphine and nicotine intake in high drinking in the dark mice is reduced by informatics-nominated and translationally relevant compounds.Frontiers in psychiatry · 2026Article
- Transcription factors implicated in substance use disorder, from immediate early genes to altered gene expression.Brain research · 2026Review
- Beyond the brain circuit: a biopsychosocial integrative review of addiction neuroscience, epigenetic mechanisms, and multidisciplinary treatment.Frontiers in psychiatry · 2026Review
- Review
- Interaction BetweenNeurology international · 2025Article
- Predicting accumulation and age at onset of amyloid-β from genetic risk and resilience for Alzheimer's disease.Research square · 2025Article
- Genetic and Epigenetic Approaches to Opioid Use Disorder.Expert reviews in molecular medicine · 2025Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Substance use disorders (SUDs) are highly prevalent and associated with excess morbidity, mortality, and economic costs. Thus, there is considerable interest in the early identification of individuals who may be more susceptible to developing SUDs and in improving personalized treatment decisions for those who have SUDs. SUDs are known to be influenced by both genetic and environmental factors. Polygenic scores (PGSs) provide a single measure of genetic liability that could be used as a biomarker in predicting disease development, progression, and treatment response. Although PGSs are rapidly being integrated into clinical practice, there is little information to guide clinicians in their responsible use and interpretation. In this Review, we discuss the potential benefits and pitfalls of the use of PGSs in the clinical care of SUDs, highlighting current research. We also provide suggestions for important considerations prior to implementing the clinical use of PGSs and recommend future directions for research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.